Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation

[1]  M. Al-Khabori,et al.  Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients. , 2017, Hematology/oncology and stem cell therapy.

[2]  M. Abecassis,et al.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation , 2016, Bone Marrow Transplantation.

[3]  S. Giralt,et al.  Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  Tammy J. Toney-Butler.  Transplantation, Hematopoietic Stem Cell , 2015 .

[5]  H. Guchelaar,et al.  Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. , 2014, Drug discovery today.

[6]  B. Sandmaier,et al.  Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. , 2014, Blood.

[7]  P. Veys,et al.  BCSH/BSBMT guideline: diagnosis and management of veno‐occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation , 2013, British journal of haematology.

[8]  D. Frappaz,et al.  Weight‐based strategy of dose administration in children using intravenous busulfan: Clinical and pharmacokinetic results , 2012, Pediatric blood & cancer.

[9]  M. Díaz-Beyá,et al.  The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  S. Napolitano,et al.  Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan , 2009, British journal of haematology.

[12]  B. Andersson,et al.  Busulfan in hematopoietic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  S. Yun,et al.  Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  P. Armand,et al.  Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. , 2007, Blood.

[15]  Edward A Copelan,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.

[16]  Soraya Dhillon,et al.  Basic pharmacokinetics , 2006 .

[17]  A. Pathare,et al.  Permanent Alopecia in Children Following Busulfan Based Conditioning Is Associated with Glutathione M1 Null Genotype. , 2005 .

[18]  R. Vianna-Jorge,et al.  Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. , 2005, Rapid communications in mass spectrometry : RCM.

[19]  B. Andersson,et al.  Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  B. George,et al.  Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. , 2004, Blood.